WHO ICTRP trial
Bioequivalence of Temozolomide capsules to Chinese cancer patients in an…
ChiCTR-IPR-15006282 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR-IPR-15006282 |
|---|---|
| Public title | Bioequivalence of Temozolomide capsules to Chinese cancer patients in an open-label, randomised, single-dose, fasting, two-way crossover study |
| Scientific title | Bioequivalence of Temozolomide capsules to Chinese variant astrocytoma and primary-care polymorphism among patients with glioblastoma in an open-label, randomised, single-dose, fasting, two-way crossover study |
| Primary sponsor | Beijing Shijitan Hospital Capital Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | I (Phase I study) |
| Countries | China |
| Conditions | Glioma |
| Interventions | Group A:T-R;Group B:R-T |
| Registration date | Mar 23, 2015 |
| Target size | Group A:12;Group B:12 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: